Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients

Abstract

Background: Although lipoprotein(a) [Lp(a)] has been considered a cardiovascular risk factor for many years, there is a paucity of data in regard to the potential risk of elevated Lp(a) in symptomatic patients with CAD. Therefore, we sought to evaluate whether elevated Lp(a) is associated with worse outcome in symptomatic patients with coronary artery disease (CAD), and to clarify the prognostic value of Lp(a) in the era of coronary artery revascularization.

Methods: 6252 consecutive subjects (59.2% male, mean age 61.2 ± 11.2 years) suspected of having CAD underwent coronary angiography. Laboratory values for lipid parameters including Lp(a) were obtained on the day of coronary angiography. Baseline risk factors, coronary angiographic findings, length of follow-up, and major adverse cardiovascular events (MACE), including cardiac death and non-fatal myocardial infarction were recorded.

Results: Over a mean follow-up period of 3.1 ± 2.2 years, there were 100 MACE (56 cardiac deaths and 44 non-fatal myocardial infarctions), with an event rate of 1.6%. In multivariate Cox regression analysis, elevated Lp(a) was a significant predictor of MACE [hazard ratio 1.773 (95% confidence interval 1.194-2.634, p=0.005)], and the addition of this factor to the model significantly increased the global х(2) value over traditional risk factors and CAD (from 79.1 to 88.7, p=0.003).

Conclusions: Elevated Lp(a) is an independent prognostic risk factor for cardiovascular events, and moreover, has incremental prognostic value in symptomatic patients with coronary artery revascularization.

Keywords: Adverse cardiac events; CABG; CAD; CI; CRT; Coronary artery disease; Coronary artery revascularization; HDL; HR; LDL; Lipoprotein(a); Lp(a); MACE; MI; OMT; Prognosis; confidence interval; coronary artery bypass graft surgery; coronary artery disease; coronary revascularization treatment; hazard ratio; high-density lipoprotein; lipoprotein(a); low-density lipoprotein; major adverse cardiovascular event; myocardial infarction; only medical treatment.